If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Kisunla ™ (donanemab-azbt) injection, for intravenous infusion
350 mg/20 mL (17.5 mg/mL)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should the starting dose of Kisunla™ (donanemab-azbt) be adjusted for amyloid level?
The recommended dose of Kisunla (donanemab) is not dependent on baseline amyloid levels, however evidence of Alzheimer's disease neuropathology is required.
See important safety information, including boxed warning, in the attached prescribing information.
Dosing is Not Dependent on Baseline Amyloid Levels
Donanemab is indicated for the treatment of Alzheimer's disease (AD). Treatment with donanemab should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease.1
Confirm the presence of amyloid beta pathology prior to initiating treatment.1
There are no dosing recommendations based on baseline amyloid level in the donanemab product labeling.1
The recommended dose of donanemab is 700 mg every 4 weeks for 3 doses, then 1400 mg every 4 weeks.1 Donanemab Dosing Schedule provides information on the dosing schedule.
Enclosed Prescribing Information
Reference
1Kisunla [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.
Date of Last Review: July 11, 2024